ENDPOINTS

Bristol Myers’ Opdualag stumbles in late-stage resected melanoma trial

Bristol Myers Squibb’s LAG-3/PD-1 targeting immunotherapy Opdualag failed to boost survival in patients with advanced skin cancer in a Phase 3 study, marking the latest flop for an approach that has a patchy study record ...

Feb 14, 2025 - 12:54
 0
Bristol Myers’ Opdualag stumbles in late-stage resected melanoma trial
Bristol Myers Squibb’s LAG-3/PD-1 targeting immunotherapy Opdualag failed to boost survival in patients with advanced skin cancer in a Phase 3 study, marking the latest flop for an approach that has a patchy study record ...
Read More

Tags:

Previous Article

Moss doesn't get a lot of love. Moss Appreciation Week in Oregon aims to change ...

Next Article

Men Actually Crave Romantic Relationships More Than Women Do

Related Posts

Exclusive: Lithuanian biotech Atrandi Biosciences raises $25M Series A

Exclusive: Lithuanian biotech Atrandi Biosciences raise...

Feb 18, 2025  0

#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa

#ASCOGU: Lilly’s early bladder cancer data hint at safe...

Feb 15, 2025  0

Illumina to lay off about 100 people; Incyte’s new AI partnership

Illumina to lay off about 100 people; Incyte’s new AI p...

Feb 20, 2025  0